CENTRIFUGAL HEART-LUNG BYPASS PUMP SAFETY UNDER REVIEW BY REP. MURTHA
This article was originally published in The Gray Sheet
Executive Summary
CENTRIFUGAL HEART-LUNG BYPASS PUMP SAFETY UNDER REVIEW BY REP. MURTHA, according to a written statement released Oct. 6 by the Pennsylvania Democrat. Rep. John Murtha said that his office will meet with FDA to discuss the possibility of requiring "manufacturers of centrifugal pumps to develop safety systems or to add warning labels to the machines." He added that he will introduce legislation requiring manufacturers to add warning labels and safety features if FDA cannot act through existing regulations.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.